User:EmayneACORN/Lee S. Schwartzberg, MD, FACP

Lee S. Schwartzberg, MD, FACP Dr. Lee S. Schwartzberg, MD, FACP, a practicing medical oncologist, is a senior partner, President and Chief Medical Office at The West Clinic in Memphis, TN and President of ACORN Research, LLC. He is board certified in Internal Medicine, Medical Oncology and Hematology.

Education
Dr. Schwartzberg attended State University of New York at Buffalo from 1969-1974, earning a B.A. in 1973 and an M.S. in 1974. He received his medical degree in 1980 from New York Medical College, then served as an intern and resident at Cornell University/North Shore University Hospital. He completed his fellowship training in medical oncology and hematology at Memorial Sloan Kettering Cancer Center in 1987, where he served as Chief Medical Resident and founding member of the institutional ethics committee.

Practice/Research
Dr. Schwartzberg is a researcher in breast cancer, with additional interests in high-dose chemotherapy, lung cancer, colorectal cancer and supportive care research. He has published more than 90 manuscripts in peer review journals.

In the early 1980s, Dr. Schwartzberg and his colleague Dr. Tauer sought to bring advancement of research to the community oncology setting. They established out-patient, high-dose chemotherapy centers throughout Memphis, providing cutting-edge, quality care to cancer patients in the Mid-South area. The West Clinic expanded its research capabilities in the 1990s, with Dr. Schwartzberg spearheading the research program.

Dr. Schwartzberg founded the Baptist Cancer Institute - Community Clinical Oncology Program in 1995. He served as Principal Investigator from 1995-2000. From 1996-2008, he acted as Medical Director of the Myelosuppression Unit and the C.A.R.E.S. (Cancer Assesment, Risk, Evaluation and Surveillance) Program at Baptist Memorial Hospital in Memphis, TN.

In 2001, Accelerated Community Oncology Research Network (ACORN) was founded with Dr. Schwartzberg serving as President. He continues to lead ACORN (now ACORN Research, LLC) in a mission to bring research capabilities to community practices nationwide. From an initial staff of 4, ACORN Research has expanded to include over 100 employees and 2 divisions: a 20-site network of community-based practices conducting Phase I-II oncology clinical trials and a CRO division.

Positions/Appointments
Dr. Schwartzberg holds an academic appointment as Clinical Professor of Medicine at The University of Tennessee Health Science Center. He is the Medical Director for the Baptist Centers for Cancer Care Cancer Genetics Program and Stem Cell Transplant Program.

In 2004, Dr. Schwartzberg founded Community Oncology, a journal focused on clinical oncology research. He has served as the Editor-in-Chief since its establishment. In 2007, he became Editor-in-Cheif of OncologySTAT.

Honors/Awards

 * Lifetime Achievement Award, Memphis Business Journal, 2010
 * Zodiac Ball Physician of the Year, American Cancer Society, 2008
 * Volunteerism and Community Service Award, American College of Physicians - Tennessee Chapter, 2007
 * Professional of the Year, Strathmore's WHO'S WHO in Hematology/Oncology, 2005 & 2006
 * Health Care Horoes Finalist, Memphis Business Journal, 2001 & 2003
 * Presidents Award, American Cancer Society, 1996
 * Henry G. Rudner Memorial Award, American Cancer Society, 1995
 * Clinical Scholar Fellowship, 1986-1987
 * National Research Service Award, 1985-1987
 * Clinical Fellowship, American Cancer Society, 1983-1984
 * Alpha Omega Alpha, 1979
 * Fellow of the American College of Physicians-American Society of Internal Medicine (ACP-ASIM)

Publications

 * 1) Liebowitz PJ, Schwartzberg LS, Bruce AK. The In vivo association of manganese with the chromosome of micrococcus radiodurans. Photochem Photobiol 23:45-50, 1976.
 * 2) Braverman AS, Schwartzberg LS, Berkowitz R. Soluble and stroma-bound globulin chains in mild and severe B Thalassemia. Hemoglobin 6:347-367, 1982.
 * 3) Huvos AG, Schwartzberg LS, Eds. Clinicopathologic Conference at Memorial Hospital: Fever and jaundice in a 22 year old woman with acute myelomonocytic leukemia. Cancer Invest 3:261-270, 1985.
 * 4) Huvos AG, Schwartzberg LS, Eds. Clinicopathologic Conference at Memorial Hospital: Hemolytic anemia, thrombocytopenia and renal failure in a patient apparently cured of anal carcinoma. Cancer Invest 3:481-489, 1985.
 * 5) Kris MG, Schwartzberg LS, Gralla RJ: The role of chemotherapy in lung cancer. Prim Care and Cancer 6:15-21, 1986.
 * 6) White DA, Schwartzberg LS, Kris MG, Bosl GJ: Acute chest pain syndrome during bleomycin infusions. Cancer 59:1582-1585, 1987.
 * 7) Kris MG, Schwartzberg LS, Gralla RJ: Small cell lung cancer. Prim Care and Cancer 7:39-46, 1987.
 * 8) Schwartzberg LS, Holbert JM. Hemorrhagic and thrombotic abnormalities of cancer. Crit Care Clin 4(1):107-28, 1988.
 * 9) Marshall GD, Jr., Schwartzberg LS, Tauer KW, Lee P, Holbert JM, West WH: LAK cell therapy - clinical studies and future potential. Prog Clin Biol Res 337:555-8, 1990.
 * 10) Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P, Altemose R, George C, Blanco R, Wittlin F, Cohen J, Muscato J, West WH: Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colon-stimulating factor. J Hematotherapy 1:3167-327, 1992.
 * 11) Bender JG To LB, Williams S, Schwartzberg LS: Defining a therapeutic dose of peripheral blood stem cells. J Hematotherapy 1:329-342, 1992.
 * 12) Oldham RK, Blumenschein G, Schwartzberg LS, Birch R, and Arnold J: Combination biotherapy utilizing interleukin-2 and alpha Interferon in patients with advanced cancer: A National Biotherapy Study Group Trial. Mol Biother, 4 (3), March 1992.
 * 13) Clark WC, Callihan T, Schwartzberg LS, Fontanesi J: Primary Intracranial Hodgkin’s lymphoma without dural attachment: case report. - J Neurosurgery 76:692-5, 1992.
 * 14) Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, Hazelton B, and West W: Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high dose chemotherapy. Bone Marrow Transplant. May, 11(5):369-374, 1993.
 * 15) Dillman RO, Church C, Oldham RK, West WH, Barth NM, Schwartzberg LS, Arnold J, Birch R, Avent RA: Experience with high-dose continuous infusion interleukin-2 in the treatment of 788 cancer patients. Cancer 71(7):2358-2370, 1993.
 * 16) Weaver C, Birch R, Schwartzberg L, Hazelton B, Palmer P, and West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients following the administration of myeloablative chemotherapy. Blood, Nov 15;86(10):3961-3969, 1995.
 * 17) Ross AA, Loudovaris M, Hazelton B, Weaver CH, Schwartzberg L, and Bender JG. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp Hematol, 23:1478-1483, 1995.
 * 18) Weaver CH, Schwartzberg LS, Li W, Hazelton B, Palmer P, and West W. High dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin’s disease. Bone Marrow Transplant, 17:715-722, 1996.
 * 19) Weaver CH, Hainsworth J, Greco FA, Schwartzberg L, Li W, Palmer P, Birch R, and West W. The treatment related mortality in 1,000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant, 19:671-678, 1997.
 * 20) Weaver CH, West WH, Schwartzberg LS, Birch R, McAneny B, Alberico T, Hainsworth J, Greco FA, Leff R, and Buckner CD. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 19:661-670, 1997.
 * 21) Weaver CH, Potz J, Redmond J, Tauer KW, Schwartzberg LS, Kaywin P, Drapkin R, Grant B, Under P, Allen C, Longin K, Zhen B, Hazelton B, Buckner CD. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ content. Bone Marrow Transplant 19(11):1103-1110, 1997.
 * 22) Weaver CH, Schwartzberg LS, Zhen B, Mangum M, Leff R, Tauer K, Rosenberg A., Pendergrass K, Kaywin P, Hainsworth J, Greco FA, West WH, and Buckner CD. High-dose chemotherapy and peripheral blood stem cell infusion in patients with Non-Hodgkin’s lymphoma: Results of outpatient treatment in community cancer centers. Bone Marrow Transplant, 20:753-760, 1997.
 * 23) Weaver CH, Greco FA, Hainsworth J, Zhen B, Baldwin P, Wittlin F, Lewis M, Schwartzberg LS, and Buckner CD. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Bone Marrow Transplant, 20:847-853, 1997.
 * 24) Weaver CH, Schwartzberg LS, Birch R, Greco A, Hainsworth J, Drapkin R, Campos L, Grapski R, Schwerkoske J, Lautersztain J, Hazelton B, Schnell F, Babcock W, and Buckner CD. Collection of peripheral blood stem cells following the administration of paclitaxel, cyclophosphamide and filgrastim in patients with breast and ovarian cancer. Biol Blood Marrow Transplant, 3:83-90, 1997.
 * 25) Weaver CH, Schwartzberg LS, Birch R, Greco FA, Rhinehart S, Hainsworth J, Beeker T, Price H, Geier L, Foster J, West J, Hazelton B, and Buckner CD. Collection of peripheral blood progenitor cells following the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients. Transfusion, 37(9):896-903, 1997.
 * 26) Weaver C, Birch R, Greco F, Schwartzberg L, McAneny B, Moore M, Oviatt D, Redmond J, George C, Alberico T, Buckner C. Mobilization and harvesting of peripheral blood stem cells: A randomized dose escalation trial of filgrastim. Br J Haematol 100:338-347, 1998.
 * 27) Weaver C, Schwartzberg L, Rhinehart S, West J, Zhen B, West W, Buckner C. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma. Bone Marrow Transplant 21:383-389, 1998.
 * 28) Weaver C, Moss T, Schwartzberg L, Zhen B, West J, Rhinehart S, Campos L, Beeker T, Lautersztain L, Buckner C. High-dose chemotherapy in patients with breast cancer: impact of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 21:1117-1124, 1998.
 * 29) Schwartzberg L, Weaver C, Birch R, Manner C, Tauer K, Beeker T, Morgan-Ihrig C, MacAneny B, Leff R, Smith R, Hainsworth J, Greco T, Schwerkoske J, Murphy M, and Buckner C. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer. J Hematother 7:141-150,1998.
 * 30) Weaver C, Schwartzberg L, Zhen B, Hazelton B, Weaver C, Tauer K, Raefsky E, Allen C, Longin K, Buckner C. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 7:241-249, 1998.
 * 31) Weaver C, Zhen B, Schwartzberg L, Leff R, Magee M, Geier L, Deaton K, Lewkow L, Buckner C. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 22:245-251, 1998.
 * 32) Weaver C, Zhen B, Schwartzberg L, Walker C, Upton S, Buckner C. A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide and G-CSF with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. Am J Clin Oncol 21:408-412, 1998.
 * 33) Schwartzberg L, Birch R, West W, Tauer K, Wittlin F, Leff R, Campos L, Rymer W, George C, Carter P, Mangum M, Greco F, Hainsworth J, Raefsky E, Blanco R, Buckner C, Weaver C. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: Outpatient Administration in Community Cancer Centers. Am J Clin Oncol, 1998; 21(5):523-531.
 * 34) Weaver C, West W, Schwartzberg L, Birch R, Buckner C. The rationale for performing autologous peripheral blood stem cell transplants in community cancer centers. The Oncologist 1998; 3(5):346-353.
 * 35) Dillman R, Nayak S, Barth N, DeLeon C, Schwartzberg L, Spitler L, Church C, O’Connor A, Beutel L. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer Biotherapy Radiopharm. 1998; Jun 13(3):165-176.
 * 36) Weaver C, Schwartzberg L, Zhen B, Franco C, Moore M, Smith R, Jr., White L, Van Amburg A, Hazelton B, Buckner CD. Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY. Bone Marrow Transplant. 1999; Mar;23(5):421-5.
 * 37) Schwartzberg L, Birch R, Tauer K, Leff R, Greco F, Hainsworth J, Raefsky E, McAneny B, Weaver Z, West J, Buckner CD, Weaver CH. Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes. Am J Clin Oncol. 1999 Apr;22(2):136-42.
 * 38) Schwartzberg L, Weaver C, Campos L, Tauer K, Smith R, Zhen B, Birch R, Murphy M, Buckner C. High-Dose chemotherapy with peripheral blood stem cell support for operable locally advanced noninflammatory carcinoma of the breast. Breast J. 1999 Jul;5(4):238-245.
 * 39) Schwartzberg L, Weaver C, Birch R, Giudice R, Sobong E, Schnell F, Kalman L, Buckner C. Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support. Am J Clin Oncol. 1999 Apr;22(2): 162-67.
 * 40) Schwartzberg L, Weaver C, Lewkow L, McAneny B, Zhen B, Birch R, West W, Tauer K, Buckner C. High-dose chemotherapy with peripheral blood stem cell support for stage III-B inflammatory carcinoma of the breast. Bone Marrow Transplant. 1999 Nov;24(9):981-7.
 * 41) Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001 Mar;91(1-2):123-30.
 * 42) Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Savan A, Hynes H, Boccia R, O’Bryne J, Colowick AB. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr;84 Suppl 1:17-23.
 * 43) Dillman RO, DeLeon C, Beutel LD, Barth NM, Schwartzberg LS, Spitler LE, Garfield DH, O’Connor AA, Nayak SK. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2): 115-23.
 * 44) Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol. 2001 Oct;40(1):17-24.
 * 45) Burgess J, Mills B, Griffith M, Mansour V, Weaver CH, Schwartzberg LS, Snyder EL, Krause DS, Yanovich S, Prilutskaya M, Umiel T, Moss TJ. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells. Cytotherapy. 2001;3(4)285-94.
 * 46) Schwartzberg LS, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, Douglas L, Tan M, Billups C, Mihalik R, Weir A, Tauer K, Shope S, Houghton, JA. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clin Cancer Res. 2002 Aug;8(8):2488-98.
 * 47) Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O’Byrne J, Rossi G, Colowick AB. Darbepoietin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002 Jul 29;87(3) 268-76.
 * 48) Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg D, Levitt D, Wedel N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003 Feb;17(2):314-8.
 * 49) Fortner B, Okon T, Ashley J, Kepler G, Chavez J, Tauer K, Clements-Thompson M, Schwartzberg L, Demarco G, Houts AC. The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage. 2003 Apr;25(4):334-43.
 * 50) Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC. The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage. 2003 Dec;26(6):1077-92.
 * 51) Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther. 2003 Nov;25(11):2781-96.
 * 52) Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L Schwartzberg L, Billups CA, Panetta JC, Stewart CF. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemother Pharmacol. 2004 Mar;53(3):253-60.
 * 53) Hesketh PJ, Arena F, Patel D, Austin M, D’Avirro P, Rossi G, Colowick A, Schwartzberg L. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004 Feb 15;100(4):859-68.
 * 54) Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L, Schwartzberg L, Billups CA, Panetta JC, Stewart CF. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemother Pharmacol. 2004 Mar;53(3)253-60.
 * 55) Fortner BV, Tauer K, Zhu L, Okon TA, Moore K, Templeton D, Schwartzberg L. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer. 2004 May 20;4(1):22.
 * 56) Fortner B, Okon T, Zhu L, Tauer K, Moore K, Templeton D, Schwartzberg L. Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice. Community Oncology, 2004 Vol.1(1)23-28.
 * 57) Fortner B, Tauer K, Zhu L, Ma L, Schwartzberg L. The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver. Community Oncology, 2004 Vol.1(4)211-216.
 * 58) Vogel C, Wojtukiewicz M, Carroll R, Tjulandin S, Barajas-Figueroa L, Wiens B, Neumann T, Schwartzberg L. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005 Feb 20;23(6):1178-84.
 * 59) Fortner B, Schwartzberg L, Tauer K, Houts A, Hackett J, Stolshek B. Impact of chemotherapy-induced neutropenia on quality of life: a prospect pilot investigation. Journal of Supportive Care in Cancer, 2005. Vol.13 (7)522-528.
 * 60) Baldwin S, Schwartzberg L, Houts A, Fortner B. Validation of the cancer care monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. Journal of Pain and Symptom Management, 2005. Vol.31(3), 207-214.
 * 61) Fortner B, Okon T, Schwartzberg L, Tauer K, Houts A. Experiencing Neutropenia: Quality of Life interviews with adult cancer patients. BMC Nursing, 2005. 4(4), doi:10.1186/1472-6955-4-4.
 * 62) Schwartzberg L, Fortner B, Houts A. Sex differences in patients who have cancer with mild anemia: symptom burden and quality of life. Supportive Cancer Therapy, 2005. Jul 1;2(4), 241-6.
 * 63) Schwartzberg L. Erythropoietic therapy: who, how, and when? Support Cancer Ther. 2006. Jan 1;3(2):125-6.
 * 64) Schwartzberg L. Neutropenia: etiology and pathogenesis. Clin Cornerstone. 2006;8 Suppl 5:S5-11. Review.
 * 65) Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol. 2006 Feb;4(2 Suppl 1):3-8.
 * 66) Fortner B, Schwartzberg L, Stepanski E, Houts A, Fu D, Bibbs T. Human resource (HR) implications of IV monoclonal antibody (MoAb( infusion reactions (IR): Interim data from a time and motion study [abstract]. Journal Supportive Oncology 2006. Vol. 4(8).
 * 67) Fortner B, Baldwin S, Schwartzberg L, Houts AC. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage. 2006 Mar;31(3):207-14.
 * 68) Elting L, Fortner B, Bosserman L, House A, Schwartzberg L. If at first you don’t succeed, don’t quit, try again: The Centers for Medicare and Medicaid Services demonstration project on quality of car-2006 and 2006. J Support Oncol. 2006 Mar;4(3):147-51.
 * 69) Nordyke R, Chang C, Chiou C, Wallace J, Yao B, Schwartzberg L. Validation of a patient satisfaction questionnaire for anemia treatment, the PSQ-An. Health Qual Life Outcomes 2006. May 3;4:28.
 * 70) Smith T, Khatcheressian J, Lyman G, Schwartzberg L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 1;24(19):3187-205.
 * 71) Fortner B, Houts A, Schwartzberg L. A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Supportive Oncol 2006 Oct; 14(9):472-8.
 * 72) Govindan R, Crowley J, Schwartzberg L et al. Phase II trial of bexarotene capsules in patients with advanced non-small cell lung cancer after failure of two or more previous therapies. J Clin Oncol. 2006 Oct 20;24(30):4848-54.
 * 73) Schwartzberg L, Fortner B, Houts A. American Society of Clinical Oncology 2007 Educational book. R. Govindan, MD (Eds.), Use of Technology to Enhance Doctor-Patient Interactions. (pp. 686-691). Chicago, Illinois.
 * 74) Dillman R, DePriest C, DeLeon C, Barth N, Schwartzberg L, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biotherapy and Radiopharmaceuticals 2007 Jun;22(3):309-21.
 * 75) Schwartzberg L. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology (Williston Park). 2007 Jul;21(8)946-53; discussion 954, 959, 962 passim. Review.
 * 76) Fortner B, Schwartzberg L, Stepanski E, Houts A. Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting. Support Cancer Ther. 2007 Sep 1;4(4):233-40.
 * 77) Schwartzberg L, Stepanski E, Fortner B, Houts A. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008 Apr;16(4):393-8.
 * 78) Mauer A, Cohen E, Ma P, Kozloff M, Schwartzberg L, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):631-6.
 * 79) Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V, et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer. 2008 Jun;8(3):234-41.
 * 80) Schwartz L, Stepanski E, Walker M, Mathias S, et al. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer. 2009 Jan:17(1):91-98.
 * 81) Hochster H,  L, Ramanathan R, Childs B, Schwartzberg L, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008 Jul 20;26(21):3523-9.
 * 82) Robinson K, Will M, van der Jagt R, Schwartzberg L, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and Mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008. Sept 20;26(27):4473-9.
 * 83) Schwartzberg L, Stepanski E, Walker M, Mathias S, Houts A, Fortner B. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer 2009. Jan;17(1):91-8.
 * 84) Schwartzberg L, Cobb P, Walker M, Stepanski E, Houts A. Patient and practice impact of capecitabine compared to Taxanes in first-/second-line chemotherapy for metastatic breast cancer. Support Care Cancer 2009. Aug:17(8):1081-1088.
 * 85) Blakely L, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson A, Walker M. A phase II trial of Pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009. Jan 21.
 * 86) Fields A, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A., et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009. April 20;27(12) 1941-7.
 * 87) Schwartzberg L, Cobb P, Senecal F, Henry D, Kulig K, Walker M, et al. Initial treatment and changes in adjuvant endocrine therapy of early stage breast cancer. Breast 2009. April; 18(2):78-83.
 * 88) Stepanski E, Walker M, Schwartzberg L, Blakely L, Ong J, Houts A. The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med. 2009. April 15;5(2): 132-6.
 * 89) Walker M, Schwartzberg L, Stepanski E, Fortner, B. A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Res Treat. 2009. May;115(2):415-22.
 * 90) Jain A, Hughes R, Sandler A, Dowlati A, Schwartzberg L, Dobbs T, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009. Jun:4(6):722-7.
 * 91) Blackwell K, Pegram M, Tan-Chiu E, Schwartzberg L, Arbushites M, Maltzman J, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. Ann Oncol. 2009 Jun;20(6):1026-31.
 * 92) Blakely L, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson A, Walker M. A Phase II trial of Pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB-IV non-small cell lung cancer. Lung Cancer. 2009 Oct;66(1):97-102.
 * 93) Stepanski E, Houts A, Schwartzberg L, Walker M, Reyes C, Blakely J. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. Clin Lung Cancer. 2009 Nov;10(6):426-32.
 * 94) Klein R, Muehlenbein C, Liepa A, Babineaux S, Wielage R, Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009 Nov;4(11):1404-14.